Resumen de acción TE1 Bio-Techne Corporation, junto con sus filiales, desarrolla, fabrica y vende reactivos, instrumentos y servicios de ciencias de la vida para los mercados de investigación, diagnóstico y bioprocesamiento de todo el mundo. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Bio-Techne Corporation Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Bio-Techne Precios históricos de las acciones Precio actual de la acción US$69.00 Máximo en las últimas 52 semanas US$78.50 Mínimo de 52 semanas US$57.50 Beta 1.27 Cambio en 1 mes -2.82% Variación en 3 meses 3.76% Cambio de 1 año 4.55% Variación en 3 años -26.98% Variación en 5 años 43.01% Variación desde la OPV 502.88%
Noticias y actualizaciones recientes
Bio-Techne Corporation to Highlight Novel Solutions for Cancer and Carrier Screening At Amp 2024 Annual Meeting & Expo Nov 14
New minor risk - Earnings quality Nov 08
Bio-Techne Corporation to Present at the Society for Immunotherapy of Cancer (SITC) 39Th Annual Meeting Nov 06
Bio-Techne Corporation Announces the Release of Clinically Relevant Spatial Biology Data Nov 05
First quarter dividend of US$0.08 announced Nov 04
First quarter 2025 earnings released: EPS: US$0.21 (vs US$0.32 in 1Q 2024) Nov 01 Ver más actualizaciones
Bio-Techne Corporation to Highlight Novel Solutions for Cancer and Carrier Screening At Amp 2024 Annual Meeting & Expo Nov 14
New minor risk - Earnings quality Nov 08
Bio-Techne Corporation to Present at the Society for Immunotherapy of Cancer (SITC) 39Th Annual Meeting Nov 06
Bio-Techne Corporation Announces the Release of Clinically Relevant Spatial Biology Data Nov 05
First quarter dividend of US$0.08 announced Nov 04
First quarter 2025 earnings released: EPS: US$0.21 (vs US$0.32 in 1Q 2024) Nov 01
Bio-Techne Corporation Declares Dividend for the Quarter Ended September 30, 2024, Payable on November 22, 2024 Oct 30
ScaleReady and Bio-Techne Corporation Announce Optimal Closed System Cytokine Packaged for Single Step Use in Closed System G-Rex® Manufacture of CAR-T and TCR Therapies Sep 16
Bio-Techne Corporation, Annual General Meeting, Oct 24, 2024 Sep 13
Fourth quarter dividend of US$0.08 announced Aug 12
Full year 2024 earnings released: EPS: US$1.07 (vs US$1.81 in FY 2023) Aug 08
Bio-Techne Corporation Declares Dividend for the Quarter Ended June 30, 2024, Payable on August 30, 2024 Aug 07
Bio-Techne Corporation Announces the Launch of the Leo™ System Jul 31
Bio-Techne Corporation to Showcase Multiple Applications of the MauriceFlex™? System at the Annual ASMS Conference May 30
Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration May 23
Investor sentiment improves as stock rises 21% May 08
Third quarter dividend of US$0.08 announced May 05
Third quarter 2024 earnings released: EPS: US$0.31 (vs US$0.45 in 3Q 2023) May 02
Bio-Techne Corporation Declares Dividend for the Quarter Ended March 31, 2024, Payable on May 24, 2024 May 01
Bio-Techne Corporation Appoints Dr. Judith Klimovsky to Board of Directors Apr 30
Now 20% overvalued Apr 30
Bio-Techne Corporation and Novomol-Dx Announce Point-of-Care Ocular Biomarker Assay Apr 27
Independent Director recently sold €733k worth of stock Mar 12
Second quarter dividend of US$0.08 announced Feb 05
Second quarter 2024 earnings released: EPS: US$0.17 (vs US$0.32 in 2Q 2023) Feb 02
Bio-Techne Corporation Announces to Pay A Dividend for the Quarter Ended December 31, 2023, Payable February 26, 2024 Feb 02
Bio-Techne Corporation Sets New Standard with the Development of A Next-Generation, Protease-Free RNAscope Spatial Multiomics Workflow Jan 29
Now 22% overvalued after recent price rise Jan 24
Bio-Techne Corporation to Report Q2, 2024 Results on Feb 01, 2024 Jan 17 Bio-Techne Corporation Appoints Matthew F. Mcmanus as President, Diagnostics and Genomics Segment, Effective January 8, 2024
Bio-Techne Corporation Announces to Pay A Dividend for the Quarter Ended September 30, 2023, Will Be Payable November 24, 2023 Nov 01
First quarter 2024 earnings released: EPS: US$0.32 (vs US$0.57 in 1Q 2023) Nov 01
Bio-Techne Corporation to Present New Data Using Lunaphore's Comet Technology at the Society for Immunotherapy of Cancer's 38th Annual Meeting Oct 27 Bio-Techne Corporation Announces Executive Changes
Bio-Techne Corporation Launches the New Maurice Chromeleon Driver Kit, Which Enables Control of its Maurice™ Instrument with the Thermo Scientific™ Chromeleon™ Chromatography Data System Sep 27
Bio-Techne Corporation, Annual General Meeting, Oct 26, 2023 Sep 14
Full year 2023 earnings released: EPS: US$1.82 (vs US$1.73 in FY 2022) Aug 09
Bio-Techne Corporation (NasdaqGS:TECH) acquired Lunaphore Technologies SA from PHC Holdings Corporation (TSE:6523) and others. Jul 11
Bio-Techne Corporation (NasdaqGS:TECH) reached an agreement to acquire Lunaphore Technologies SA. Jun 23
Bio-Techne Corporation Announces Launch of Kappa and Lambda Rnascope Ish Probes as Analyte Specific Reagents (Asrs) for the Detection of Immunoglobulin Kappa and Lambda Light Chains mRNA May 11
Bio-Techne Declares Quarterly Dividend, Payable May 26, 2023 May 04
Third quarter 2023 earnings released: EPS: US$0.45 (vs US$0.39 in 3Q 2022) May 03
Second quarter 2023 earnings released: EPS: US$0.32 (vs US$0.51 in 2Q 2022) Feb 05
Bio-Techne Corporation Declares Dividend for the Quarter Ended December 31, 2022, Payable on February 27, 2023 Feb 03
Bio-Techne Corporation Announces Executive Changes, Effective March 3, 2023 Feb 01
Bio-Techne Launches the Mauriceflex™ System, Adding Cief Fractionation Capability to the Gold Standard Maurice Assays Jan 27
Bio-Techne Corporation Launches RNAscope Plus Assay to Advance Gene Therapy Development Jan 11
Bio-Techne Releases MitoBrilliant Fluorescent Dyes, Providing A Next-Generation Tool for Imaging Mitochondria in Live and Fixed Cells Dec 06
Insufficient new directors Nov 16
First quarter 2023 earnings released: EPS: US$2.28 (vs US$1.78 in 1Q 2022) Nov 02
Bio-Techne Corporation Declares Dividend for the Quarter Ended September 30, 2022, Payable on November 28, 2022 Nov 02
Bio-Techne Corporation Announces the Introduction of 3 Novel TSA Vivid Fluorophores for Highly Sensitive Fluorescent Detection of RNAs and Proteins in Cells and Tissues Oct 13
Bio-Techne Corporation and PROGEN Introduce New Simple Plex AAV Viral Titer Assays Oct 12
Bio-Techne Corporation Commercializes Automated Multi-Omic Rnascope Assays for Spatial Visualization of RNA and Protein Biomarkers in FFPE Tissues Oct 07
Bio-Techne Corporation, Annual General Meeting, Oct 27, 2022 Sep 02
Bio-Techne Corporation Announces Release of Quantist Luminex Data Analysis Software Aug 19
Full year 2022 earnings released: EPS: US$6.94 (vs US$3.62 in FY 2021) Aug 05 Bio-Techne Corporation Announces Dividend for the Quarter Ended June 30, 2022, Payable on August 29, 2022
Insufficient new directors Aug 01
Bio-Techne Launches New Turbo CE-SDS ™ Cartridge, Accelerating Protein Purity Analysis Throughput by 400% Jul 13
Bio-Techne Announces Launch of the CE-IVD RNAscope ISH Probe High Risk HPV Assay for Head and Neck Cancer Jul 07
Bio-Techne Corporation (NasdaqGS:TECH) completed the acquisition of Namocell, Inc. Jul 06
Insufficient new directors Jul 02 Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell 1000 Growth-Defensive Index
Bio-Techne Corporation (NasdaqGS:TECH) reached an agreement to acquire Namocell, Inc. Jun 23
Bio-Techne Corporation Announces the Publication of A Global Study in the Journal of Electrophoresis May 26
Independent Chairman of the Board recently bought €100k worth of stock May 12
Third quarter 2022 earnings released: EPS: US$1.55 (vs US$1.18 in 3Q 2021) May 05
Bio-Techne Corporation Declares Quarterly Dividend for the Quarter Ended March 31, 2022, Payable on May 27, 2022 May 05
Bio-Techne and Cygnus Technologies, Part of Maravai Lifesciences, Introduces New Simple Plex Hek 293 Hcp 3G Immunoassay Apr 13
Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Feb 04 Bio-Techne Corporation Declares Dividend for the Quarter Ended December 31, 2021, Payable on February 25, 2022
Now 20% undervalued after recent price drop Jan 28
Bio-Techne Corporation Announces Commercial Release of High Sensitivity Fluorescent Detection Stellar NIR / IR™ Modules for Jess Automated Western Blotting System Jan 19
First quarter 2022 earnings released: EPS US$1.78 (vs US$0.87 in 1Q 2021) Nov 03
Bio-Techne Launches ExCellerate iPSC Expansion Medium Sep 15
President of Protein Sciences Segment recently sold €656k worth of stock Sep 03
Full year 2021 earnings released: EPS US$3.62 (vs US$6.00 in FY 2020) Aug 06 Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell 3000E Value Index
Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell 1000 Value-Defensive Index Jun 27
President of Diagnostics & Genomics recently sold €288k worth of stock Jun 12
President of Diagnostics & Genomics recently sold €293k worth of stock May 28
Bio-Techne Corporation Announces Results of A Multisite Evaluation Study of the AmplideX May 11
Third quarter 2021 earnings released: EPS US$1.18 (vs US$0.95 in 3Q 2020) May 08
Bio-Techne Corporation Declares Dividend for the Quarter Ended March 31, 2021, Payable on May 28, 2021 May 07
Bio-Techne Announces Commercial Release of Novel DNAscope™ in situ Hybridization Assays for Chromogenic Detection of DNA Copy Number and Structural Variations Apr 29
Bio-Techne Corporation (NasdaqGS:TECH) has reached an agreement to acquire Asuragen, Inc for $320 million. Mar 05
Bio-Techne's Exosome Diagnostics Laboratory Announces Reimbursement Contract With Humana Mar 03
Bio-Techne and Luminary Therapeutics Sign License Agreement for Use of Bio-Techne's Tcbuster™ for the Development of Luminary's Car-T Cell Therapies Feb 24
New 90-day high: €342 Feb 18
Bio-Techne Corporation Announces That the U.S. Food and Drug Administration Added Covid-Seroklir to the Emergency Use Authorization Feb 11 Rentabilidad de los accionistas TE1 DE Life Sciences Mercado DE 7D -0.7% 0.2% 0.7% 1Y 4.5% -2.4% 8.4%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: TE1 superó a la industria German Life Sciences, que obtuvo un rendimiento del -2.4% el año pasado.
Rentabilidad vs. Mercado: TE1 obtuvo unos resultados inferiores a los del mercado German, que fueron del 8.4% el año pasado.
Volatilidad de los precios Is TE1's price volatile compared to industry and market? TE1 volatility TE1 Average Weekly Movement 5.3% Life Sciences Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.0% 10% least volatile stocks in DE Market 2.4%
Precio estable de las acciones: TE1 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de TE1 (5%) se ha mantenido estable durante el año pasado.
Acerca de la empresa Bio-Techne Corporation, junto con sus filiales, desarrolla, fabrica y vende reactivos, instrumentos y servicios de ciencias de la vida para los mercados de investigación, diagnóstico y bioprocesamiento de todo el mundo. La empresa opera a través de dos segmentos: Ciencias de las Proteínas y Diagnóstico y Genómica. El segmento de Ciencias de las Proteínas desarrolla y fabrica reactivos biológicos utilizados en diversos aspectos de la investigación en ciencias de la vida, el diagnóstico y la terapia celular y génica, como citocinas y factores de crecimiento, anticuerpos, pequeñas moléculas, sueros para cultivo de tejidos y tecnologías de selección celular.
Mostrar más Resumen de fundamentos de Bio-Techne Corporation ¿Cómo se comparan los beneficios e ingresos de Bio-Techne con su capitalización de mercado? Estadísticas fundamentales de TE1 Capitalización bursátil €11.15b Beneficios(TTM ) €146.82m Ingresos (TTM ) €1.14b
75.4x Ratio precio-beneficio (PE)
9.7x Ratio precio-ventas (PS) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de TE1 Ingresos US$1.17b Coste de los ingresos US$398.40m Beneficio bruto US$773.19m Otros gastos US$622.50m Beneficios US$150.68m
Últimos beneficios comunicados
Sep 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) 0.95 Margen bruto 65.99% Margen de beneficio neto 12.86% Ratio deuda/patrimonio 14.0%
¿Cómo se ha desempeñado TE1 a largo plazo?
Ver rendimiento histórico y comparativa Dividendos
0.4% Rentabilidad actual por dividendo
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2025/01/02 11:08 Precio de las acciones al final del día 2025/01/02 00:00 Beneficios 2024/09/30 Ingresos anuales 2024/06/30
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas Bio-Techne Corporation está cubierta por 27 analistas. 14 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución David Toung Argus Research Company James Francis Mainwaring Atlantic Equities LLP Catherine Ramsey Schulte Baird
Mostrar 24 más analistas 
